Looking to publish in Immunopharmacology and Immunotoxicology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginImmunopharmacology and Immunotoxicology publishes manuscripts on drug discovery, pre-clinical and clinical development of agents targeting the immune system, and immunotoxicology of defined drug compounds. It focuses on anti-inflammatory treatments, cancer immunotherapy, vaccines, small molecules, biologics, and cell-based therapies, and covers immune-mediated diseases, cancer immunology, infections, transplantation, allergy, chronic kidney disease, neurodegenerative disorders, immunodeficiencies, neurology, inflammatory atherosclerosis, and related areas. The journal considers mechanism-of-action studies, in vitro and pre-clinical animal studies, and non-interventional and interventional clinical studies.
Looking to publish in Immunopharmacology and Immunotoxicology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Immunopharmacology and Immunotoxicology accepts the following article types. Click on an article type to view submission instructions.
Original Manuscripts
Mini-Reviews
Review
Clinical Trials
Research Article
Brief Communication
Clinical Cases
Clinical Note
Letter
Recent Publications
Vildagliptin attenuates thioacetamide-induced hepatic fibrosis in rats: associations with AMPK/SIRT1/Nrf2 and STAT3/TGF-β1 signaling
Mohannad A. Almikhlafi, May A. Alsayb, Sara A. Almadani, Tahani Saeedi, Mohammed H. Alsubhi, Alyaa Farouk Hessin, Marwa Mahmoud Fawzy Atta, Reda MS Korany, Hany M. Fayed, Sally A. El Awdan, Hossein M. Elbadawy
Application of antibiotic-loaded bone cement in unicompartmental knee arthroplasty: inhibiting IL-6 levels and reducing postoperative infection rate
Dexiang Zhang, Yang Shen, Shaobing Zhang, Xiaolong Xiong
Inhibition of xanthine oxidase protects against heatstroke-related acute kidney injury
Wenting Chen, Yongwei Song, Yue Jia, Fei Xiao, Mingyang Zhang, Chun Lan, Xuesen Yang, Ling Wang, Huanzi Dai
Repurposing the third-generation EGFR inhibitor osimertinib to synergize with paclitaxel and extend survival in anaplastic thyroid cancer
Ran Jie, Xiawei Shen
Thioperamide, a histamine H3 receptor antagonist, attenuates neuroimmune activation and inflammation in the SOD1 G93A mouse model of amyotrophic lateral sclerosis
Abdullah A. Aldossari, Abdulaziz M. S. Alsaad, Ahmed Nadeem, Mushtaq A. Ansari, Sabry M. Attia, Saleh A. Bakheet, Haneen A. Al-Mazroua, Mohammed M. Almutairi, Hussain N. Alhamami, Wedad S. Sarawi, Hatun A. Alomar, Majed Ali Algonaiah, Ali A. Alshamrani, Alaa A. Alanteet, Marwa H. Hussein, Mohamed A. Mahmoud, Sheikh F. Ahmad
Frequently asked questions
How long does it take to publish?
Optional Accelerated Publication offers a final decision in as little as 3 weeks from submission, with peer review in approximately 2 weeks, online publication usually 1-2 weeks after acceptance, first proofs within 5 working days, and proof corrections requested within 48 hours.
Reformat to Immunopharmacology and Immunotoxicology using Livewrite PremiumIs a cover letter required?
Journals may require authors to sign a letter certifying that legal and ethical requirements for humane treatment of animals have been met.
Reformat to Immunopharmacology and Immunotoxicology using Livewrite PremiumWhat are the publication costs?
Institutional online-only subscription is USD 6,695.00 and print & online subscription is USD 9,791.00.
Reformat to Immunopharmacology and Immunotoxicology using Livewrite Premium